The company will start its confirmatory bexobrutideg study in June.

Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.

Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.

The group impresses in ovarian and endometrial cancers.

After setbacks, cema-cel might have a path to approval in lymphoma.

Optimum-02 virtually replicates phase 1, and a filing will follow.